MARKET

SHRXF

SHRXF

Sharp Therapeutics Corp
OTCMQB
0.750
NaN%
Closed 09:30 07/24 EDT
OPEN
--
PREV CLOSE
0.750
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
3.000
52 WEEK LOW
0.329
MARKET CAP
22.51M
P/E (TTM)
-3.5782
1D
5D
1M
3M
1Y
5Y
1D
Sharp Therapeutics holds annual shareholder meeting
PUBT · 3d ago
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
Newsfile · 3d ago
Sharp Therapeutics plans non-brokered private placement raising up to C$1.37 million at minimum C$0.91/share
PUBT · 07/15 12:05
Sharp Therapeutics postpones annual shareholder meeting to July 21 from June 30
PUBT · 06/30 21:01
Sharp Therapeutics posts preclinical data on small-molecule Niemann-Pick type C drug approach
PUBT · 05/28 20:05
SHARP THERAPEUTICS PRESENTS NEW PRECLINICAL DATA SUPPORTING NOVEL SMALL-MOLECULE THERAPEUTIC APPROACH FOR NIEMANN-PICK DISEASE TYPE C
Reuters · 05/28 20:00
Sharp Therapeutics shifts Gaucher, GBA1 Parkinson’s programs to alternative lead compound
Reuters · 04/10 21:17
Sharp Therapeutics drops '901 candidate, advances alternative for Gaucher and GBA1 Parkinson's
Reuters · 04/10 21:05
More
About SHRXF
Sharp Therapeutics Corp. is a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases. Its discovery platform combines high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. Its technology includes CoreX assay technology, AlloChem compound libraries, and mine data system and machine learning layer. Its advanced programs include a small molecule that prevents the degradation of the neuroprotective protein progranulin, thus increasing progranulin levels preventing neurodegeneration, and a small molecule that restores activity of mutated GCase protein (mutation and loss of activity of GCase is the genetic cause of Gaucher’s disease).

Webull offers Sharp Therapeutics Corp stock information, including OTCMQB: SHRXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SHRXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SHRXF stock methods without spending real money on the virtual paper trading platform.